Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 2nd Preview)
-
Gene editing regulation
The FDA issued draft guidance outlining how sponsors should pursue approvals and postapproval management for individualized human genome editing products, aimed at rare genetic diseases. The proposal—FDA-2026-D-11783—introduces a framework for Biologics License Applications (BLAs) that can cover patient-specific edits without requiring a separate trial for every variant class.
-
Late-stage oncology readout
Trastuzumab rezetecan delivered a substantial progression-free survival benefit in HER2-low advanced breast cancer versus physician’s-choice chemotherapy in the phase 3 HORIZON-Breast06 trial. Presented at the ESMO Congress 2026 and published in JAMA, the study enrolled 551 patients and met its coprimary endpoints for chemotherapy-naïve patients and the overall population.
-
Merger-fueled oncology win
Genmab surged to record highs after petosemtamab plus Keytruda reduced the risk of death by about half versus Keytruda alone in first-line head and neck squamous cell carcinoma with PD-L1 positivity. In an early analysis, the combination met dual main objectives on response rates and survival, marking another positive late-stage readout for the company.
-
Rare disease biotech funding and clinic entry
Setara Biosciences launched with $90 million in funding and a lead program in the clinic targeting Charcot-Marie-Tooth disease type 2C and overactive bladder. The small-molecule asset originated from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals, linking Setara’s opening franchise to a larger pharma deal pipeline.
-
Robotics microsurgery expansion
Medical Microinstruments (MMI) raised $125 million in Series D financing to expand the reach of its Symani Surgical System and explore new microsurgery applications. The company also outlined an experimental approach that includes investigating microsurgical treatment for Alzheimer’s disease, extending its platform beyond existing surgical indications.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.